-
Something wrong with this record ?
Screening and semiquantitative analysis of drugs and drugs of abuse in human serum samples using gas chromatography-mass spectrometry
V. Marešová, J. Chadt, E. Nováková
Language English Country Sweden
Document type Research Support, Non-U.S. Gov't
Grant support
NR9365
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
- MeSH
- Solid Phase Extraction MeSH
- Fluoroacetates MeSH
- Calibration MeSH
- Trifluoroacetic Acid chemistry MeSH
- Pharmaceutical Preparations blood MeSH
- Humans MeSH
- Substance Abuse Detection methods MeSH
- Gas Chromatography-Mass Spectrometry MeSH
- Substance-Related Disorders blood MeSH
- Reproducibility of Results MeSH
- Trimethylsilyl Compounds chemistry MeSH
- Check Tag
- Humans MeSH
- Publication type
- Research Support, Non-U.S. Gov't MeSH
OBJECTIVES: The purpose of this study is to develop the gas chromatographic-mass spectrometric method (GC-MS) for screening and semiquantification of drugs and drugs of abuse in human serum. METHOD: GC-MS method after liquid-liquid extraction (LLE) and derivatization with N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) is presented for screening as well as identification and semiquantification of the most frequently used drugs and drugs of abuse in human serum. RESULTS: Bovine serum spiked with ephedrine (EPHE), 3,4-methylenedioxymethamphetamine (MDMA), guaifenesin (GUAIF), tramadol (TRAM), phenobarbital (PHENO), amitriptyline (AMITR), cocaine (COCA), mirtazapine (MIRTA), dothiepin (DOTH), citalopram (CITAL), clomipramine (CLOMI), bromazepam (BMZPM), diazepam (DZPM), codeine (COD), morphine (MORPH), levomepromazine (LEVO), zolpidem (ZOLP), clozapine (CLOZP), alprazolam (ALPZM) was used for the recovery and repeatability study and for preparation of calibration curves of individual compounds or their TMS derivatives. Recoveries were tested on concentration levels 0.05, 0.1 and 0.5 microg/mL (n=6) and established in range 72.0-98.0%. Repeatabilities expressed as relative standard deviations (RSDs) measured at concentration levels 0.05, 0.1 and 0.5 microg/ mL (n=6) were lower than 10.0%. The calibration curves for analytes or their TMS derivatives were linear in concentration range 0.025-2.000 microg/mL (except of EPHE 2TMS, MDMA TMS, MORPH 2TMS, BMZPM TMS, ALPZM) with correlation coefficients exceeding 0.99. The limit of quantification (LOQ) for analytes used for evaluation study was 0.025 microg/mL (except analytes mentioned above). CONCLUSIONS: The GC-MS method presented here is allowing screening, identification and semiquantification of the most commonly encountered drugs and drugs of abuse in human serum and can be successfully applied to analysis of real samples from clinical and forensic toxicology cases.
- 000
- 01747naa 2200361 a 4500
- 001
- bmc11006260
- 003
- CZ-PrNML
- 005
- 20140326130836.0
- 008
- 110401s2008 sw e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sw
- 100 1_
- $a Marešová, Věra, $d 1955- $7 jo2003163134
- 245 10
- $a Screening and semiquantitative analysis of drugs and drugs of abuse in human serum samples using gas chromatography-mass spectrometry / $c V. Marešová, J. Chadt, E. Nováková
- 314 __
- $a Institute of Forensic Medicine and Toxicology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. vera.maresova@lf1.cuni.cz
- 520 9_
- $a OBJECTIVES: The purpose of this study is to develop the gas chromatographic-mass spectrometric method (GC-MS) for screening and semiquantification of drugs and drugs of abuse in human serum. METHOD: GC-MS method after liquid-liquid extraction (LLE) and derivatization with N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) is presented for screening as well as identification and semiquantification of the most frequently used drugs and drugs of abuse in human serum. RESULTS: Bovine serum spiked with ephedrine (EPHE), 3,4-methylenedioxymethamphetamine (MDMA), guaifenesin (GUAIF), tramadol (TRAM), phenobarbital (PHENO), amitriptyline (AMITR), cocaine (COCA), mirtazapine (MIRTA), dothiepin (DOTH), citalopram (CITAL), clomipramine (CLOMI), bromazepam (BMZPM), diazepam (DZPM), codeine (COD), morphine (MORPH), levomepromazine (LEVO), zolpidem (ZOLP), clozapine (CLOZP), alprazolam (ALPZM) was used for the recovery and repeatability study and for preparation of calibration curves of individual compounds or their TMS derivatives. Recoveries were tested on concentration levels 0.05, 0.1 and 0.5 microg/mL (n=6) and established in range 72.0-98.0%. Repeatabilities expressed as relative standard deviations (RSDs) measured at concentration levels 0.05, 0.1 and 0.5 microg/ mL (n=6) were lower than 10.0%. The calibration curves for analytes or their TMS derivatives were linear in concentration range 0.025-2.000 microg/mL (except of EPHE 2TMS, MDMA TMS, MORPH 2TMS, BMZPM TMS, ALPZM) with correlation coefficients exceeding 0.99. The limit of quantification (LOQ) for analytes used for evaluation study was 0.025 microg/mL (except analytes mentioned above). CONCLUSIONS: The GC-MS method presented here is allowing screening, identification and semiquantification of the most commonly encountered drugs and drugs of abuse in human serum and can be successfully applied to analysis of real samples from clinical and forensic toxicology cases.
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a kalibrace $7 D002138
- 650 _2
- $a plynová chromatografie s hmotnostně spektrometrickou detekcí $7 D008401
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a léčivé přípravky $x krev $7 D004364
- 650 _2
- $a reprodukovatelnost výsledků $7 D015203
- 650 _2
- $a extrakce na pevné fázi $7 D052616
- 650 _2
- $a odhalování abúzu drog $x metody $7 D015813
- 650 _2
- $a poruchy spojené s užíváním psychoaktivních látek $x krev $7 D019966
- 650 _2
- $a kyselina trifluoroctová $x chemie $7 D014269
- 650 _2
- $a trimethylsilylové sloučeniny $x chemie $7 D014297
- 650 _2
- $a fluoracetáty $7 D005463
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Chadt, Jiří. $7 _AN059737
- 700 1_
- $a Nováková, Eva, $d 1945- $7 jo2003163135
- 773 0_
- $t Neuroendocrinology Letters $g Roč. 29, č. 5 (2008), s. 749-754 $x 0172-780X $w MED00168352
- 910 __
- $a ABA008 $b x $y 2 $z 0
- 990 __
- $a 20110414101706 $b ABA008
- 991 __
- $a 20140326130910 $b ABA008
- 999 __
- $a ok $b bmc $g 833867 $s 698353
- BAS __
- $a 3
- BMC __
- $a 2008 $b 29 $c 5 $d 749-754 $i 0172-780X $m Neuro-endocrinology letters $n Neuro-endocrinol. lett. $x MED00168352
- GRA __
- $a NR9365 $p MZ0
- LZP __
- $a 2011-1B09/dkjp